Truncated CSF3R mutations are a very rare event in de novo AML, while RUNX1 mutations are most frequent among patients with secondary AML (sAML) after chemotherapy or radiation therapy, which represents about 30% of adult AML cases. Here, CSF3R is linked to acute myeloid leukemia.